Brian Freed

Brian Freed

Company: RheumaGen

Job title: Co-Founder & Chief Scientific Officer


Introducing Genetic Tolerance Through HLA Gene Editing: Evaluating the Preclinical Data & Regulatory Feedback 2:45 pm

Identifying antigen-specific HLA gene-editing targets with bioinformatics and novel assays Editing the HLA gene without immunosuppression or rejection Reviewing the preclinical data and FDA feedback for Rheumagen’s lead indication of treatment-resistant rheumatoid arthritisRead more

day: Conference Day Two

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.